This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.0 (amino acid transport disorder, Fanconi(-De Toni)(-Debré) syndrome) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | De Toni-Debré-Fanconi syndrome, Generalized proximal tubular dysfunction, Amino acid transport disorder, Complex tubulopathy, Renal Fanconi syndrome |
| C. Adult onset | Likelihood of first onset in adulthood is not low — Fanconi syndrome due to acquired causes (light chain deposition due to multiple myeloma, drug-induced such as tenofovir, lead or cadmium poisoning, autoimmune diseases) is often first diagnosed in adults, especially the middle-aged and elderly; congenital forms (secondary to underlying diseases such as cystinosis, galactosemia, Wilson disease) mainly present in childhood, but diagnosis in adulthood is also possible in mild cases. |
| 1. History | Described by Fanconi in 1936 → De Toni (1933), Debré (1934) → synthesis by Dent and Wachter in 1952 → accumulation of cases due to cystinosis, Wilson disease and tenofovir → elucidation of molecular transporters in the 2020s. |
| 2. Causes | Congenital: cystinosis (the most common childhood cause), galactosemia, fructose intolerance, Wilson disease, tyrosinemia type 1, Lowe syndrome. Acquired: tenofovir, ifosfamide, valproic acid, multiple myeloma, heavy metals (lead, cadmium, mercury), hypoxia. |
| 3. Genetics | Varies by causative disease: cystinosis (CTNS, 17p13, AR), galactosemia (GALT, 9p13, AR), Wilson disease (ATP7B, 13q14, AR), Lowe syndrome (OCRL, Xq26, XR). Common damage to proximal tubule transporters (NaPi-IIa, NHE3, SGLT2, etc.). |
| 4. General epidemiology | Fanconi syndrome itself is an uncommon rare disease; childhood presentation due to cystinosis in 1 in 100,000–200,000 births per year; acquired (drug-induced) in 0.5–2% of patients on antiretroviral therapy; tends to be underdiagnosed worldwide. |
| 5. Pathophysiology | Impaired energy metabolism of proximal tubule cells or direct damage to transporters → reduced ATP production → global loss of reabsorption dependent on active transport: amino acids (generalized aminoaciduria), glucose (renal glucosuria), phosphate (hypophosphatemia), uric acid (hypouricemia), bicarbonate (proximal tubular acidosis). |
| 6. Symptoms | Growth delay, rickets/osteomalacia (phosphate loss), muscle weakness (hypokalemia), polydipsia and polyuria, dehydration, symptoms of acidosis (nausea, vomiting, lethargy). Ocular, neurological and hepatic symptoms depending on the underlying disease. Acquired forms in adulthood: bone pain, proximal muscle weakness, decline in renal function. |
| 7. Signs | Growth impairment, knock knees/genu varum (rickets), Looser zones (osteomalacia), muscle weakness. Urinalysis: glucosuria (normal blood glucose), generalized aminoaciduria, low-molecular-weight proteinuria, phosphaturia. Blood: hypophosphatemia, hypokalemia, hypouricemia, normal anion gap metabolic acidosis. |
| 8. Screening | Urine uric acid/creatinine ratio, urine amino acid analysis (quantitative amino acid chromatography), urine glucose (under normal blood glucose conditions), urine phosphate/creatinine ratio, urine β2-microglobulin (low-molecular-weight proteinuria). Simultaneous serum measurements to search for the underlying cause. |
| 9. Diagnosis | Calculation of TINU (tubular ion reabsorption rate); quantitative urine amino acids (liquid chromatography-mass spectrometry); tubular reabsorption of phosphate (TRP) < 85%; confirmation of proximal tubular acidosis (urine pH, fractional bicarbonate); genetic testing for the underlying cause; kidney biopsy (if needed). |
| 10. Treatment | Treatment of the underlying cause (cystinosis: cysteamine; Wilson disease: chelation therapy; drug-induced: discontinuation of the causative drug). Correction of electrolytes and acid-base balance: sodium bicarbonate, potassium citrate. Phosphate supplementation (sodium and potassium phosphate, active vitamin D). Children with growth delay: consider GH. Nutritional support. |
| 11. Prognosis | Varies greatly depending on the underlying cause. Untreated cystinosis leads to end-stage renal failure around age 10. Improvement possible when acquired causes (drugs) are removed. Risk of osteomalacia and fractures with persistent hypophosphatemia. Growth and renal function can be preserved with early diagnosis and correction of the cause. |
| 12. Prevention | Primary: genetic counseling (for hereditary causes such as cystinosis). Secondary: regular monitoring of renal function and urine in patients on tenofovir, screening of occupational groups exposed to heavy metals. Tertiary: early phosphate and bicarbonate supplementation to prevent progression of rickets and metabolic acidosis; regular bone density measurement. |
| 13. References | Klootwijk & Kleta. Nephrol Dial Transplant. 2020 … and 9 other papers |
The name Fanconi syndrome derives from the Swiss pediatrician Guido Fanconi (1892–1979). However, because the first descriptions of this syndrome were made almost simultaneously in 1931 and 1933 by Giovanni De Toni of Italy, Robert Debré of France and Fanconi, the triple name 'De Toni-Debré-Fanconi syndrome' is also used. In 1936, Fanconi systematically described cases in children with cystinosis combining glycosuria, aminoaciduria, phosphaturia and rickets, establishing the clinical entity of this syndrome.
In 1952, Charles Edward Dent and G. A. Wachter confirmed by chromatography that generalized aminoaciduria involving all amino acids, rather than a single amino acid, is the key feature of this syndrome. Around the same time, Charles Pik and colleagues physiologically characterized the global loss of tubular function. From the 1960s, various metabolic disorders such as galactosemia, Wilson disease and tyrosinemia were found to cause this syndrome, and in 1973, when cystinosis was confirmed to be due to deficiency of the lysosomal cystine transporter, molecular understanding began.
In the 1980s–1990s, antiviral agents (ifosfamide, cidofovir), and later in the 2000s the anti-HIV drug tenofovir (tenofovir disoproxil fumarate), emerged as major causes of acquired Fanconi syndrome. After the association between tenofovir and Fanconi syndrome was formally reported in 2003, monitoring for tubular toxicity in HIV-infected patients became standardized. In the 2010s, idiopathic renal glucosuria due to GLUT2 mutations (Fanconi-Bickel syndrome) was classified as a separate hereditary cause, and molecular biological characterization of proximal tubule transporters (NHE3, NaPi-IIa, NaPi-IIc, OAT, etc.) deepened. In the 2020s, the cellular-level pathogenesis of Fanconi syndrome is being re-examined through single-cell RNA sequencing (scRNA-seq) and organoid models.
In Korea, Fanconi syndrome is registered and managed under Special Copayment Reduction by causative disease, and with advances in pediatric nephrology and genetic metabolic medicine, diagnoses of causative diseases such as cystinosis and Lowe syndrome are increasing. Reported acquired causes in Korea include antituberculosis drugs (including ifosfamide), antiretroviral drugs and cases of heavy metal contamination of herbal medicines.
Fanconi syndrome is not a single disease but the final common pathway of various causative diseases that cause global damage to proximal tubular function. Causes are broadly classified into congenital (hereditary) and acquired causes.
Among congenital causes, cystinosis (nephropathic cystinosis) is the most common cause in children; CTNS gene mutations cause cystine to accumulate in lysosomes, damaging proximal tubule cells. In galactosemia (GALT deficiency), accumulation of galactose-1-phosphate causes tubular toxicity. In hereditary fructose intolerance (ALDOB deficiency), accumulation of fructose-1-phosphate after fructose exposure causes acute tubular toxicity. In Wilson disease (ATP7B deficiency), excess copper deposition damages the proximal tubule. In tyrosinemia type 1 (FAH deficiency), succinylacetone exerts toxicity on tubular cells. In Lowe syndrome (OCRL deficiency), deficiency of phosphatidylinositol 4,5-bisphosphate phosphatase impairs endocytic trafficking in the proximal tubule, causing Fanconi syndrome. Mitochondrial diseases (complex I, III, IV deficiency) also impair tubular ATP production through defective oxidative phosphorylation.
Acquired causes are broadly divided into drugs, poisoning, and immune and infiltrative diseases. Among drugs, the anti-HIV drug tenofovir (tenofovir disoproxil fumarate, TDF) is the most important cause, inhibiting the energy metabolism of proximal tubule cells through inhibition of mitochondrial DNA polymerase γ. With the anticancer drug ifosfamide, the metabolite chloroacetaldehyde exerts direct tubular toxicity. Cisplatin, valproic acid and streptozocin are also reported causes. Among heavy metals, lead, cadmium, mercury and uranium directly inhibit mitochondrial function and transporters. Among immunoglobulin deposition diseases, light chain deposition in multiple myeloma causes proximal tubule cell damage and is an important cause of adult Fanconi syndrome. Rarely, amyloidosis and Sjögren syndrome can also cause tubular damage.
Because Fanconi syndrome is not a single genetic disease but a tubular function phenotype shared by many genetic diseases, its genetic basis varies depending on the causative disease.
Cystinosis, the most common congenital cause, is caused by mutations in the CTNS gene (encoding the cystinosin protein) located on the short arm of chromosome 17 (17p13.2) and is inherited in an autosomal recessive manner. In about 60–65% of Western European patients, a 57 kb deletion including exons 1–10 of the CTNS gene is observed. In Asian patients, including those in Korea, point mutations are more frequent.
Galactosemia is an autosomal recessive disease caused by mutations in the GALT gene (galactose-1-phosphate uridylyltransferase) on the short arm of chromosome 9 (9p13), and the most common mutation is Q188R.
Wilson disease is an autosomal recessive disease caused by mutations in the ATP7B gene (copper-transporting ATPase) on the long arm of chromosome 13 (13q14.3); the most common mutation worldwide is H1069Q (Eastern Europe), and in Korea R778L and others have been reported.
Fanconi syndrome due to mitochondrial diseases arises from mutations in nuclear DNA or mitochondrial DNA, including mtDNA deletions (Pearson syndrome) and POLG (mitochondrial DNA polymerase γ) mutations.
The transport function of the proximal tubule is made up of SLC family transporters (SLC5A2/SGLT2, SLC34A1/NaPi-IIa, SLC7A8/LAT2, SLC3A2/4F2hc, etc.), the SLC9A3/NHE3 exchanger, Na+/K+-ATPase and others. Fanconi syndrome is complete when these transporters are damaged by direct mutation (idiopathic Fanconi-Bickel syndrome: SLC2A2 deficiency) or lose function due to cellular energy deficiency or exposure to toxic substances. In acquired Fanconi syndrome, mitochondrial dysfunction and cellular energy deficiency act as the common mechanism instead of specific transporter mutations.
The overall prevalence of Fanconi syndrome is difficult to determine precisely and is tallied by causative disease. The incidence of cystinosis, the most common single cause of childhood Fanconi syndrome, is about 1 in 100,000–200,000 births in Western Europe. In the United States, it occurs in about 100–200 newborns per year, and an estimated 2,000 patients are living worldwide. Lowe syndrome (OCRL deficiency) has a frequency of about 1 in 500,000 male births.
Among acquired forms of Fanconi syndrome, the drug-induced form has increased particularly with the widespread use of tenofovir disoproxil fumarate (TDF) in HIV treatment. Decline in renal function and tubular damage are reported in about 0.5–2% of HIV patients taking TDF, and progression to complete Fanconi syndrome is at about 0.3%. This frequency increases in patients with risk factors such as preexisting kidney disease, low body weight and coadministration of ritonavir. Tenofovir-related tubular toxicity is also observed in Korean HIV patients receiving antiretroviral therapy, and since the 2010s the frequency has tended to decrease with switching to tenofovir alafenamide (TAF).
Adult Fanconi syndrome due to multiple myeloma is estimated to occur in about 1–2% of patients with multiple myeloma. In adult patients with Fanconi syndrome, hematologic malignancies including multiple myeloma must be differentiated, and in particular, in newly developed Fanconi syndrome after age 50 the possibility of hematologic malignancy should not be ruled out. In Korea, some hereditary causes such as cystinosis are identified through the pediatric rare metabolic disease registration system, but registration and epidemiological data for Fanconi syndrome as a whole remain insufficient.
The common pathogenic mechanism of Fanconi syndrome is the global loss of energy-dependent transport processes of proximal tubule cells. Normal proximal tubule cells consume enormous amounts of ATP to reabsorb more than 99% of the glucose, phosphate, amino acids, uric acid, bicarbonate and low-molecular-weight proteins in the glomerular filtrate, and this depends on mitochondrial oxidative phosphorylation.
In cystinosis, excessive accumulation of cystine in lysosomes causes apoptosis and cell shrinkage (atrophy). Cystine crystals also exert direct mitochondrial toxicity, inhibiting ATP production. As a result, Na+/K+-ATPase activity decreases, intracellular Na+ concentration rises, and the driving force of Na+-dependent cotransporters (SGLT2, NaPi-IIa, B0AT1, etc.) is lost. This leads to simultaneous loss of reabsorption of glucose, phosphate, bicarbonate and amino acids.
In the acquired mechanism due to tenofovir, TDF is activated in proximal tubule cells to tenofovir diphosphate (TFV-DP), which inhibits mitochondrial DNA polymerase γ (POLG). When mitochondrial DNA replication decreases, the number of subunits of electron transport chain complexes I–IV decreases and the efficiency of oxidative phosphorylation falls. When the intracellular ATP/ADP ratio decreases, the membrane voltage gradient is lost and Na+-dependent cotransport loses function all at once.
Regarding the mechanism of phosphate loss, loss of function of the NaPi-IIa (SLC34A1) and NaPi-IIc (SLC34A3) cotransporters reduces phosphate reabsorption, and the blood phosphate concentration falls, causing hypophosphatemia independent of FGF23. In the long term, hypophosphatemia interferes with mineral deposition in the skeleton, causing rickets in children and osteomalacia in adults. Bicarbonate loss causes type 1 proximal renal tubular acidosis (pRTA), characterized by normal anion gap metabolic acidosis in the blood and fractional urinary bicarbonate of 15% or more.
The clinical symptoms of Fanconi syndrome vary depending on age, the type of causative disease and the severity of loss of tubular function. Throughout the clinical picture, systemic symptoms due to the causative disease and metabolic symptoms due to loss of tubular function appear in combination.
Metabolic symptoms: Rickets in children due to hypophosphatemia is the most noticeable early symptom, appearing as leg deformities (knock knees or bowlegs), growth delay, spinal curvature and bone pain. Metabolic acidosis causes loss of appetite, nausea, vomiting and fatigue, and in severe cases is accompanied by hyperventilation. Hypokalemia causes muscle weakness, constipation and, rarely, abnormal ECGs.
Tubular symptoms: Polydipsia and polyuria, due to reduced tubular concentrating ability and solute diuresis, are common early symptoms of Fanconi syndrome. In infants, they may appear as feeding refusal, preoccupation with fluid intake and excessive urine in diapers. Glucose is detected in the urine, but blood glucose is normal (renal glucosuria), distinguishing it from diabetes mellitus.
Symptoms of acquired forms in adults: In tenofovir-induced Fanconi syndrome, fatigue, myalgia (hypophosphatemia and mitochondrial myopathy), low back pain and bone pain progressing slowly over several months precede the diagnosis. Fanconi syndrome developing after transplantation in patients with end-stage renal failure is due to tubular toxicity related to immunosuppressants (tacrolimus, sirolimus) or antivirals.
Symptoms specific to each causative disease: Photophobia due to corneal cystine crystal deposition in cystinosis, Kayser-Fleischer rings in Wilson disease, and congenital cataracts and intellectual disability in Lowe syndrome appear together with Fanconi syndrome. Galactosemia is accompanied by neonatal jaundice and liver failure, and tyrosinemia type 1 by a risk of hepatocellular carcinoma.
The physical signs of Fanconi syndrome vary depending on the degree of metabolic abnormality and the systemic involvement of the causative disease.
Musculoskeletal signs: In children, signs of hypophosphatemic rickets are widening of the wrist metaphyses (metaphyseal flaring), enlargement of the costochondral junctions (rachitic rosary), knock knees/bowlegs and gait abnormalities. In adults, osteomalacia is confirmed by Looser zones (pseudofractures). Muscle weakness is particularly prominent in proximal muscle groups (quadriceps, biceps), making it difficult to rise from sitting and to climb stairs.
Urinalysis signs: On dipstick testing, glucose positive (normal blood glucose) and protein positive (low-molecular-weight proteinuria). On urine microscopy, red blood cells and cellular casts are absent or minimal. Quantitative urine amino acid analysis confirms a marked increase in all amino acids (generalized aminoaciduria). Low-molecular-weight proteinuria (tubular proteinuria), in which low-molecular-weight proteins such as β2-microglobulin are markedly increased in the urine, is useful for distinguishing Fanconi syndrome from glomerular proteinuria.
Serum abnormalities: Hypophosphatemia (1.5–2.0 mg/dL or below versus normal 2.5–4.5 mg/dL), hypokalemia (especially ifosfamide- or tenofovir-induced), hypouricemia (renal hypouricemia 0.5–2.0 mg/dL), metabolic acidosis (decreased HCO₃⁻, low pH, normal anion gap). Elevated alkaline phosphatase (ALP) suggests active rickets/osteomalacia.
Imaging findings: Lower limb X-rays show epiphyseal irregularity, bowing of long bones and cortical bone loss. DXA (dual-energy X-ray absorptiometry) shows reduced bone density. Nephrocalcinosis may appear on abdominal ultrasound in chronic Fanconi syndrome. On ophthalmologic slit-lamp examination, corneal cystine crystals characteristic of cystinosis are observed.
There is no universal screening test for Fanconi syndrome, and a stepwise testing approach based on clinical suspicion is recommended.
Step 1 — simple urinalysis screening: Glucose positive on urine dipstick despite normal blood glucose (renal glucosuria) is a key clue to Fanconi syndrome. If protein is positive, check for low-molecular-weight proteinuria (tubular proteinuria). A urine pH persistently 6 or higher suggests proximal tubular acidosis (pRTA).
Step 2 — quantitative tubular function tests: Confirm generalized aminoaciduria by quantitative urine amino acids (liquid chromatography-mass spectrometry, LC-MS/MS). Calculate the tubular reabsorption of phosphate using the urine/serum phosphate ratio (TRP = 1 - [U_P×S_Cr/(S_P×U_Cr)]) (normal >85%). Urine β2-microglobulin (normal <0.3 mg/L; tens to hundreds of mg/L in Fanconi syndrome). Calculate the fractional excretion of uric acid (FEUA) using the urine/serum uric acid ratio (normal <10%; elevated in Fanconi syndrome). Calculate the fractional excretion of bicarbonate (FE_HCO₃) (normal <5%).
Step 3 — screening to identify the cause: Serum copper/ceruloplasmin (Wilson disease), serum amino acids/organic acids (tyrosinemia, galactosemia), leukocyte free cystine measurement (cystinosis), ophthalmologic slit-lamp examination (corneal cystine crystals, KF rings), serum and urine protein electrophoresis (multiple myeloma), mitochondrial metabolic markers (lactate, pyruvate). Medication history (TDF, ifosfamide) and occupational heavy metal exposure history must also be investigated.
Fanconi syndrome is diagnosed in two steps: objectively confirming the loss of multiple tubular functions, and then identifying the causative disease.
Criteria for confirming loss of tubular function: There are no formal single diagnostic criteria, but Fanconi syndrome is diagnosed when 3 or more of the following items are confirmed: (1) renal glucosuria (under normal blood glucose conditions), (2) generalized aminoaciduria, (3) low-molecular-weight proteinuria (β2-microglobulin, α1-microglobulin), (4) reduced tubular reabsorption of phosphate (TRP <85%), (5) increased fractional excretion of uric acid (FEUA >10%), (6) normal anion gap metabolic acidosis (elevated FE_HCO₃). Cases with all 4 classic findings (glucosuria, aminoaciduria, phosphaturia, proximal tubular acidosis) are called 'complete Fanconi syndrome,' and those with only some are called 'incomplete Fanconi syndrome.'
Diagnosis of the causative disease: In children, galactosemia, tyrosinemia and others are identified in conjunction with newborn metabolic screening (NBS) results. Leukocyte free cystine measurement (normal <0.2 nmol cystine/mg protein; 0.5–2.0 or higher in cystinosis) is the confirmatory test for cystinosis. Genetic testing (CTNS, ATP7B, OCRL, GALT, FAH, etc.) is performed stepwise according to clinical suspicion, and next-generation sequencing (NGS) panels are efficient. Kidney biopsy is useful for identifying secondary causes (light chain deposition, multiple myeloma, amyloidosis) in adult Fanconi syndrome of unclear cause.
Treatment of Fanconi syndrome consists of specific treatment of the underlying cause and conservative electrolyte and nutritional treatment for the loss of tubular function.
Treatment by underlying cause: In cystinosis, oral cysteamine (50–90 mg/kg/day, maximum 1.95 g/m²/day) is the key treatment, depleting lysosomal cystine to suppress cell damage. Early initiation immediately after diagnosis is the rule, and cysteamine eye drops are used separately for ocular cystine crystals. In Wilson disease, copper is chelated with D-penicillamine or trientine, or copper absorption is inhibited with zinc supplementation. In galactosemia, a galactose-restricted diet prevents progression of tubular damage. In drug-induced (TDF, etc.) Fanconi syndrome, tubular function may recover within weeks to months after immediate discontinuation of the causative drug. In light chain deposition Fanconi syndrome associated with multiple myeloma, treatment of the plasma cell neoplasm (bortezomib-based regimens) is key to recovery of tubular function.
Correction of electrolytes and acid-base balance: Proximal tubular acidosis is corrected with oral sodium bicarbonate or potassium citrate (target HCO₃⁻ >18 mEq/L). Correction of hypokalemia: potassium citrate or potassium chloride supplementation. Hypophosphatemia: oral neutral sodium and potassium phosphate supplementation (25–70 mg/kg/day, in divided doses) combined with active vitamin D (1,25-OH₂-vitamin D₃, calcitriol) 0.25–1.0 μg/day to promote intestinal phosphate absorption and prevent hypocalcemia. Calcium supplementation is also considered to support bone remodeling.
Nutritional support and growth management: In infants and children, adequate calorie and protein intake is important for catch-up growth. Growth hormone (GH) therapy may be given in some patients when renal function is preserved.
The prognosis of Fanconi syndrome varies greatly depending on the type of causative disease, the time of diagnosis and treatment adherence.
Fanconi syndrome due to cystinosis: Without early cysteamine treatment, children reach end-stage renal disease (ESRD) around age 10 and subsequently need kidney transplantation. After kidney transplantation, multisystem involvement of muscle, eyes, central nervous system, pancreas, liver and others progresses if cysteamine treatment is not continued. In patients who start cysteamine before diagnosis (within the first year of life), the time to ESRD is greatly extended (to the 20s or later) and quality of life improves. A long-term follow-up study recently published in 2025 reported that the dialysis rate at age 30 in the early treatment group was reduced by more than 40% compared with the untreated group.
Drug-induced acquired Fanconi syndrome: In tenofovir-related tubular damage, tubular function often recovers within 3–6 months after discontinuation of the causative drug. However, in patients in whom chronic renal failure has progressed due to continued exposure, irreversible decline in renal function may remain. The ifosfamide-induced form is dose-dependent, and a proportion of children with lasting long-term tubular damage has been reported.
Common prognostic factors: The more severe the phosphate loss and the more delayed the treatment, the higher the risk of osteomalacia and fractures. Chronic metabolic acidosis affects growth failure, muscle wasting and acceleration of protein catabolism. When decline in renal function coexists, comprehensive management of chronic renal failure is needed.
Prevention of Fanconi syndrome focuses on early detection and elimination of the causative disease and on preventing progression of complications.
Primary prevention: In families with a known hereditary cause, prenatal or preimplantation genetic testing (PGT) for cystinosis, galactosemia and others can be considered. When galactosemia is detected on newborn metabolic screening (NBS in Korea), an immediate galactose-restricted diet can prevent the development of Fanconi syndrome. Cystinosis is included in NBS in some countries, and in Korea as well early testing is recommended in high-risk families.
Secondary prevention: In HIV patients using tenofovir (TDF), tubular toxicity is detected early through regular (every 3–6 months) monitoring of the urine protein/creatinine ratio, β2-microglobulin, serum creatinine and serum phosphate. When abnormalities are found, switching to tenofovir alafenamide (TAF) or replacement with an abacavir-based regimen is considered. In occupational groups exposed to heavy metals, regular monitoring of blood lead and cadmium levels and exposure reduction measures are recommended.
Tertiary prevention: In established Fanconi syndrome, phosphate and vitamin D supplementation is maintained without interruption to prevent progression of rickets and osteomalacia, and regular bone density testing and imaging evaluation are performed. Education on maintaining adherence is important because correction of acidosis and electrolyte abnormalities has positive effects on growth, muscle strength and cognitive development. In patients with cystinosis, a multidisciplinary team approach involving ophthalmology, nephrology, neurology, endocrinology and gastroenterology is essential for preventing multisystem complications.
Klootwijk ED, Kleta R. Fanconi syndrome: a molecular pathophysiology update. Nephrol Dial Transplant. 2020;35(10):1660–1668. DOI: 10.1093/ndt/gfz170
Devuyst O, Luciani A. Novel Fanconi renotubular syndromes provide insights in proximal tubule pathophysiology. Am J Physiol Renal Physiol. 2021;320(4):F653–F663. DOI: 10.1152/ajprenal.00214.2020
Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002;347(2):111–121. DOI: 10.1056/NEJMra020552 PMID: 12110740.
Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant. 2013;28(3):505–517. DOI: 10.1093/ndt/gfs526
Rodriguez-Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13(8):2160–2170. DOI: 10.1097/01.asn.0000023430.92674.e5 PMID: 12138150.
Kose E, Kose M, Coşkun T, et al. An uncommon cause of Fanconi syndrome: tenofovir-induced tubular toxicity. Turk J Pediatr. 2019;61(4):609–613. DOI: 10.24953/turkjped.2019.04.020
Foreman JW. Fanconi Syndrome. Pediatr Clin North Am. 2019;66(1):159–167. DOI: 10.1016/j.pcl.2018.09.007 PMID: 30454741.
Luciani A, Devuyst O. Fanconi syndrome: from mechanisms to disease. Kidney Int. 2022;102(3):490–502. DOI: 10.1016/j.kint.2022.04.037
Mishra K, Bhatt GC, Kapoor K. Fanconi syndrome: a review. Indian J Nephrol. 2021;31(5):409–416. DOI: 10.4103/ijn.ijn_270_20
Hall AM, Unwin RJ. The not so 'Glorious' past of the renal Fanconi syndrome. Nephron Physiol. 2007;105(1):1–6. DOI: 10.1159/000096990 PMID: 17077638.